Humanigen Inc (OTCMKTS:HGEN) announced Friday that the official journal of the American Society of Hematology, known simply as "blood", has published an article highlighting a drug therapy the company is developing that’s designed to reduce dangerous side effects of a cancer treatment involving altered T cells.
The company said the article by Omar Ahmed entitled “CAR-T Cell Neurotoxicity: Hope is on the Horizon” was published on May 16 in blood, which is is widely regarded as a premier journal in hematology. Ahmed is Humanigen's vice president of portfolio strategy, clinical, medical and scientic affairs.
Humanigen, which is based in Burlingame, California, said the article puts the spotlight on the unmet need to mitigate T cell (CAR-T)-induced neurotoxicity using GM-CSF neutralization therapy.
“GM-CSF neutralization could be a next-generation strategy to potentially improve the efficacy, safety, and cost-effectiveness of CAR-T therapy,” said Humanigen CEO Cameron Durrant.
The company is developing monoclonal antibodies to improve CAR-T cancer therapies and oncology treatments. Its key drug candidate is lenzilumab, a recombinant monoclonal antibody that neutralizes a substance that promotes growth of white blood cells but is also tied to inflammations that can occur during CAR-T therapies and lead to side effects.
Humanigen said the article highlighted the potential of GM-CSF:
- Severe neurotoxicity is a negative prognostic factor for overall survival with chimeric antigen receptor T-cell (CAR-T) therapy.
- Prolonged exposure of corticosteroids for severe neurotoxicity may negatively influence overall survival.
- GM-CSF neutralization identified as a potential next-generation strategy to reduce CAR-T induced neurotoxicity while simultaneously improving the efficacy and durability of the response.
Humanigen's stock recently traded down 4.4% to $1.09 a share on the OTC markets.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham